NextCure, Inc. (NASDAQ:NXTC) Short Interest Update

NextCure, Inc. (NASDAQ:NXTC) saw a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 46,066 shares, a decline of 68.9% from the August 15th total of 148,136 shares. Based on an average trading volume of 115,778 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.4% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Weiss Ratings downgraded shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. HC Wainwright reiterated a “buy” rating on shares of NextCure in a report on Thursday, August 13th. Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Finally, Wall Street Zen raised shares of NextCure from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, NextCure has an average rating of “Hold” and an average target price of $19.00.

Insider Buying and Selling at NextCure

In related news, major shareholder Adar1 Capital Management, Llc acquired 292,850 shares of NextCure stock in a transaction dated Thursday, July 30th. The shares were acquired at an average cost of $4.93 per share, for a total transaction of $1,443,750.50. Following the completion of the transaction, the insider directly owned 686,116 shares of the company’s stock, valued at $3,382,551.88. The trade was a 74.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders acquired 346,761 shares of company stock valued at $1,710,807 over the last ninety days. Insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On NextCure

An institutional investor recently raised its position in NextCure stock. Renaissance Technologies LLC boosted its stake in NextCure, Inc. (NASDAQ:NXTC) by 80.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 60,534 shares of the company’s stock after purchasing an additional 26,900 shares during the quarter. Renaissance Technologies LLC owned about 1.68% of NextCure worth $647,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 42.65% of the company’s stock.

NextCure Stock Down 5.1%

Shares of NXTC stock traded down $0.36 during mid-day trading on Monday, hitting $6.64. 90,561 shares of the company’s stock were exchanged, compared to its average volume of 102,145. The stock has a market cap of $23.97 million, a price-to-earnings ratio of -0.76 and a beta of 1.33. NextCure has a fifty-two week low of $1.55 and a fifty-two week high of $15.74. The stock has a 50-day simple moving average of $5.86 and a two-hundred day simple moving average of $7.43.

NextCure (NASDAQ:NXTC) last released its earnings results on Thursday, August 6th. The company reported ($2.80) EPS for the quarter, missing the consensus estimate of ($1.95) by ($0.85).

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.